Provided by Tiger Trade Technology Pte. Ltd.

Hutchison China Meditech

13.81
-0.3500-2.47%
Post-market: 13.810.00000.00%16:10 EDT
Volume:31.59K
Turnover:438.64K
Market Cap:2.41B
PE:5.31
High:14.14
Open:13.99
Low:13.72
Close:14.16
52wk High:19.50
52wk Low:11.51
Shares:174.43M
Float Shares:104.00M
Volume Ratio:1.40
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.60
EPS(LYR):2.60
ROE:45.25%
ROA:-1.62%
PB:1.95
PE(LYR):5.31

Loading ...

Hutchmed discontinues all active tazemetostat clinical trials

TIPRANKS
·
Mar 09

CLSA Trims HUTCHMED Target Price to HK$30.40, Keeps Outperform Rating

Stock News
·
Mar 09

Guotai Haitong Sticks to Its Buy Rating for HUTCHMED (China) (HCM)

TIPRANKS
·
Mar 09

HUTCHMED Announces Executive Reshuffle: Dr. Yansi Ya to Assume Senior and Lead Independent Director Role

Stock News
·
Mar 06

Daiwa Capital Markets Adjusts HUTCHMED Target Price to HK$26, Citing Consistent Annual Performance

Stock News
·
Mar 06

Hong Kong Market Announcement Highlights | JD Group Reports 13% Revenue Growth to 1.3091 Trillion Yuan for 2025

Stock News
·
Mar 06

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

GlobeNewswire
·
Mar 05

Hutchmed 2025 Earnings Rise, Revenue Falls

MT Newswires Live
·
Mar 05

HUTCHMED Reports 2025 Financial Results with $457 Million Net Profit Attributable to Shareholders

Stock News
·
Mar 05

Earnings Flash (HCM) Hutchmed Posts 2025 Total Revenue $548.5M, vs. FactSet Est of $563.7M

MT Newswires Live
·
Mar 05

Press Release: HUTCHMED Reports 2025 Full Year Results and Business Updates

Dow Jones
·
Mar 05

Hutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors

MT Newswires Live
·
Mar 04

HUTCHMED Initiates Global Trial for Novel PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Solid Tumors

Stock News
·
Mar 04

Asure Software Confronts AI Threat to Usage-Based Revenues and HCM Demand

TIPRANKS
·
Feb 28

Press Release: Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

Dow Jones
·
Feb 26

Earning Preview: Hutchison China Meditech this quarter’s revenue is expected to increase by 0%, and institutional views are bullish

Earnings Agent
·
Feb 26

MYQORZO: EC Approval, Differentiated Label, and Global HCM Expansion Support Buy on CYTK

TIPRANKS
·
Feb 17

Cytokinetics Wins European Approval for MYQORZO in HCM

TIPRANKS
·
Feb 17

HCM IV Acquisition Corp. Announces Closing of $287,500,000 Initial Public Offering

GlobeNewswire
·
Feb 14

Asure Software to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

GlobeNewswire
·
Feb 13